추천 제품
Quality Level
양식
solid
농도
18-20% Fe (T)
음이온 미량물
chloride (Cl-): ≤500 mg/kg
양이온 미량물
Ca: ≤100 mg/kg
Cd: ≤50 mg/kg
Co: ≤50 mg/kg
Cu: ≤50 mg/kg
K: ≤500 mg/kg
Na: ≤200 mg/kg
Ni: ≤100 mg/kg
Pb: ≤50 mg/kg
Zn: ≤50 mg/kg
작용기
hydroxyl
SMILES string
OC12CC(=O)O[Fe](OC(=O)C1)OC2=O
InChI
1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3
InChI key
NPFOYSMITVOQOS-UHFFFAOYSA-K
유사한 제품을 찾으십니까? 방문 제품 비교 안내
애플리케이션
Iron(III) citrate tribasic monohydrate may be used as the source of iron, in one of the compositions, used during the preparation of perfusion solutions.
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Eye Irrit. 2
Storage Class Code
13 - Non Combustible Solids
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
이미 열람한 고객
A E Gómez-Ayala et al.
Laboratory animals, 32(1), 72-79 (1998-03-03)
The effects of iron deficiency on the absorption of different dietary sources of iron were studied, together with the interactions between iron, calcium, phosphorus, magnesium, copper and zinc in the jejunum-ileum of control and iron-deficient rats. In this study, three
Tatsuya Fukushima et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(42), 16829-16834 (2012-10-03)
Citrate is a common biomolecule that chelates Fe(III). Many bacteria and plants use ferric citrate to fulfill their nutritional requirement for iron. Only the Escherichia coli ferric citrate outer-membrane transport protein FecA has been characterized; little is known about other
Akio Iida et al.
American journal of nephrology, 37(4), 346-358 (2013-04-04)
Ferric citrate hydrate (JTT-751) is being developed as a treatment for hyperphosphatemia in chronic kidney disease patients, and shows serum phosphorus-reducing effects on hyperphosphatemia in hemodialysis patients. We examined whether JTT-751 could reduce phosphorus absorption in normal rats and prevent
Keitaro Yokoyama et al.
American journal of nephrology, 36(5), 478-487 (2012-11-14)
JTT-751 (ferric citrate hydrate) is a novel oral, iron-based phosphate binder being developed for the treatment of hyperphosphatemia among chronic kidney disease patients who are on dialysis. This study investigated the dose-response and safety of JTT-751 among Japanese hemodialysis patients.
Jamie P Dwyer et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 759-766 (2013-02-02)
Most dialysis patients require phosphate binders to control hyperphosphatemia. Ferric citrate has been tested in phase 2 trials as a phosphate binder. This trial was designed as a dose-response and efficacy trial. Prospective, phase 3, multicenter, open-label, randomized clinical trial.
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.